Treatment of NTM Respiratory Infections with Inhaled Drug Delivery

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1R43AI132067-01
Agency Tracking Number: R43AI132067
Amount: $450,000.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NIAID
Solicitation Number: PA16-302
Timeline
Solicitation Year: 2016
Award Year: 2017
Award Start Date (Proposal Award Date): 2017-02-06
Award End Date (Contract End Date): 2019-07-31
Small Business Information
401 MOUNTAIN VIEW AVE, Longmont, CO, 80501-3318
DUNS: 073872538
HUBZone Owned: N
Woman Owned: Y
Socially and Economically Disadvantaged: N
Principal Investigator
 BRIAN HANSEN
 (970) 461-5012
 aerophase@hotmail.com
Business Contact
 JEANNINE HANSEN
Phone: (303) 651-1791
Email: info@aerophase.com
Research Institution
N/A
Abstract
Project Summary AbstractDescriptionSignificanceNon tuberculous mycobacteriaNTMrespiratory infections is increasing across the globeIn the USin those overyears oldannual prevalence of pulmonary NTM disease increased significantly fromtocasesbetweenwith Hawaii having the highest prevalence atcasesPulmonary NTM istimes more common in womenThese numbers are likely underestimated because of a lack of mandatory reporting in the U STreatment of non tuberculous mycobacterial lung disease is challenging for several reasons including the relative resistance to currently available drugs and the difficulty in tolerating prolonged treatment with multiple drugsThe only oral drugs with reliable activity against Mabscessus complex an NTM are the macrolides and clofazimineSimilar to that for Mavium complexclofazimine was found to synergize with clarithromycin or amikacin against Mabscessus Clofazimine is an attractive agent for treatment of NTM respiratory infections including Mabscessus but cutaneous and internal organ accumulation from high oral doses cause significant toxicityHigh oral doses are required to reach effective concentrations in the lungsInhaled doses of clofazimine have the potential to reach immediate treatment concentrations in the lungs with inhaled low doses that do not have significant systemic toxicityPreliminary DataAerophase has recently demonstrated that innovative aerosol formulations of clofazimine with a new type of aerosol drug inhaler can treat TB respiratory infections without side effects from systemic toxicityThe new clofazimine formulation and aerosol device has demonstrated sustained pulmonary treatment concentration and an aerosol size range that can target the entire lung with clofazimine even alveolar regionsThe Aerophase inhaled aerosol delivery method holds great promise to mitigate toxicity and allow for safe clofazimine administration directly targeted to the site of infectionSpecific AimsThe first aim of this project is to treat NTM respiratory infections with inhaled clofazimine much more effectively than oral clofazimine with much lower inhaled doseThe second aim is to develop a small pocket sized metered dose inhaler with drug formulationaerosol sizeand dose optimized to treat NTM respiratory infectionsThe third aim will test in vivo efficacy of inhaled clofazimine in combination with other drugs

* Information listed above is at the time of submission. *

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government